INGN vs. CLGN, COCH, SMTI, MLSS, RBOT, ZJYL, CAPR, CLLS, QIPT, and DRTS
Should you be buying Inogen stock or one of its competitors? The main competitors of Inogen include CollPlant Biotechnologies (CLGN), Envoy Medical (COCH), Sanara MedTech (SMTI), Milestone Scientific (MLSS), Vicarious Surgical (RBOT), Jin Medical International (ZJYL), Capricor Therapeutics (CAPR), Cellectis (CLLS), Quipt Home Medical (QIPT), and Alpha Tau Medical (DRTS). These companies are all part of the "medical" sector.
CollPlant Biotechnologies (NASDAQ:CLGN) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.
In the previous week, Inogen had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Inogen and 2 mentions for CollPlant Biotechnologies. Inogen's average media sentiment score of 0.94 beat CollPlant Biotechnologies' score of 0.32 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.
Inogen received 253 more outperform votes than CollPlant Biotechnologies when rated by MarketBeat users. Likewise, 70.44% of users gave Inogen an outperform vote while only 58.59% of users gave CollPlant Biotechnologies an outperform vote.
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 1.0% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
CollPlant Biotechnologies has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
CollPlant Biotechnologies currently has a consensus target price of $11.00, indicating a potential upside of 75.72%. Inogen has a consensus target price of $7.00, indicating a potential downside of 19.35%. Given Inogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than Inogen.
CollPlant Biotechnologies has higher earnings, but lower revenue than Inogen. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Inogen has a net margin of -30.07% compared to Inogen's net margin of -64.05%. Inogen's return on equity of -22.17% beat CollPlant Biotechnologies' return on equity.
Summary
CollPlant Biotechnologies beats Inogen on 9 of the 17 factors compared between the two stocks.
Get Inogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
